Trial NCT04729725

View at ClinicalTrials.gov 
Org. Study IDs: 2020-0649
Secondary IDs: 2020-0649 NCI-2020-10859

Last trial update was posted on 2023-08-14

MeSH Interventions

Antibodies Antibodies, Monoclonal Cemiplimab

MeSH Conditions

Neoplasms

Other Conditions

Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm

Stopping Reasons

The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID